AMGEN Inc

NASDAQ: AMGN
$297.78
-$10.03 (-3.3%)
Closing Price on February 6, 2025

AMGN Articles

ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Jon OggAny time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one sense the new form of class...
Jon OggThis will be an interesting week for Wall Street analyst coverage as many traders, investors and analysts are out ahead of Labor Day. Still, we are seeing a surprising number of research calls...
ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc....
ThinkstockWith the Federal Reserve reminding investors yesterday that it can raise or lower asset purchases in its quantitative easing program based on the data, all eyes shift to tomorrow’s...
July 31, 2013: U.S. equity markets opened higher this morning as traders and investors this afternoon’s announcement from the FOMC. In Europe, the unemployment rate in the eurozone was unchanged at...
July 30, 2013: U.S. equity markets opened higher this morning as traders and investors wait for tomorrow’s announcement from the FOMC. There was little economic data published today. In the U.S.,...
courtesy of FordThe equity analysts and strategists at UBS A.G. (NYSE: UBS) expect to see U.S. equities continue to conform largely to the “1994 Playbook” in which stocks meander higher after...
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company...
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers...
July 1, 2013: U.S. equity markets opened higher this morning after a blast of economic data from both Asia and Europe. In China, June manufacturing PMI slid lower. Japan’s economics minister said...
ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ:...
ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28%...
U.S. equity markets opened lower this morning on relatively little economic data. In Europe, Germany reported that industrial production rose 1.2%, while a house price index in the U.K.rose 1.1%...
ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating billions upon billions in annual sales in the United States alone. Some...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.